Irvine, CA-based Masimo Corporation (MASI - Free Report) recently reported that Dubai Health Authority (DHA) introduced Masimo Patient SafetyNet, a supplemental remote monitoring and clinician notification system, at two hospitals in Dubai. DHA is a government organization that oversees the healthcare systems of Dubai.
Patients are being monitored by Masimo Patient SafetyNet, the latest cutting-edge remote monitoring and wireless notification system designed for doctors. The system is intended to assist hospitals to prevent injuries and deaths related with failure to rescue events, a frequent medical error.
Patient SafetyNet aids in keeping inmates secure by continuously and non-invasively monitoring their basic physiological condition. The system can monitor as many as 80 patients to timely detect abnormalities and variances that indicate deteriorating health.
The moment a patient’s health starts deteriorating, the system automatically transmits wireless messages to the smart phone of the concerned technician. This elicits a prompt and possibly life sustaining response from the caregiver. It has been established that Patient SafetyNet cuts down traumatic critical occurrences by 65% and expensive transfers to the Intensive Care Unit by 48%.
Patient SafetyNet system consists of a bedside patient monitor and a non-invasive patient sensor, which continuously reports vital physiological statistics, such as total hemoglobin (SpHb), carboxyhemoglobin (SpCO), oxygen content (SpOC) and pulse rate, among others.
Masimo SafetyNet offering places the company in an advantageous position to be the dominant global player in the pulse oximetry market. Additionally, the company’s complementary portfolio of products and services is likely to assist in strengthening its market position and achieving high productivity to better compete with rivals like Edwards Lifesciences Corporation (EW - Free Report) , CryoLife, Inc. and Edap Tms S.a. (EDAP - Free Report) .
The addition of non-invasive parameters is expected to act as a long-term barrier to entry and drive substantial growth. The expanded pulse oximetry utilization into non-critical care areas of hospital represents another growth driver. Shipments have been growing at a steady rate fueled by new contracts. Moreover, recurring revenues from sale of consumables are increasing.
On the negative side, a weak macro environment raises concern and competition remains intense. Moreover, Masimo partly depends upon its Original Equipment Manufacturers (“OEM”) partners for a part of its sales. In conclusion, its valuation, which already factors in its robust growth prospects, offers limited upside potential at this time.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Irvine, CA-based Masimo Corporation (MASI - Free Report) recently reported that Dubai Health Authority (DHA) introduced Masimo Patient SafetyNet, a supplemental remote monitoring and clinician notification system, at two hospitals in Dubai. DHA is a government organization that oversees the healthcare systems of Dubai.
Patients are being monitored by Masimo Patient SafetyNet, the latest cutting-edge remote monitoring and wireless notification system designed for doctors. The system is intended to assist hospitals to prevent injuries and deaths related with failure to rescue events, a frequent medical error.
Patient SafetyNet aids in keeping inmates secure by continuously and non-invasively monitoring their basic physiological condition. The system can monitor as many as 80 patients to timely detect abnormalities and variances that indicate deteriorating health.
The moment a patient’s health starts deteriorating, the system automatically transmits wireless messages to the smart phone of the concerned technician. This elicits a prompt and possibly life sustaining response from the caregiver. It has been established that Patient SafetyNet cuts down traumatic critical occurrences by 65% and expensive transfers to the Intensive Care Unit by 48%.
Patient SafetyNet system consists of a bedside patient monitor and a non-invasive patient sensor, which continuously reports vital physiological statistics, such as total hemoglobin (SpHb), carboxyhemoglobin (SpCO), oxygen content (SpOC) and pulse rate, among others.
Masimo SafetyNet offering places the company in an advantageous position to be the dominant global player in the pulse oximetry market. Additionally, the company’s complementary portfolio of products and services is likely to assist in strengthening its market position and achieving high productivity to better compete with rivals like Edwards Lifesciences Corporation (EW - Free Report) , CryoLife, Inc. and Edap Tms S.a. (EDAP - Free Report) .
The addition of non-invasive parameters is expected to act as a long-term barrier to entry and drive substantial growth. The expanded pulse oximetry utilization into non-critical care areas of hospital represents another growth driver. Shipments have been growing at a steady rate fueled by new contracts. Moreover, recurring revenues from sale of consumables are increasing.
On the negative side, a weak macro environment raises concern and competition remains intense. Moreover, Masimo partly depends upon its Original Equipment Manufacturers (“OEM”) partners for a part of its sales. In conclusion, its valuation, which already factors in its robust growth prospects, offers limited upside potential at this time.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on EW - FREE
Get the latest research report on MASI - FREE
Get the latest research report on EDAP - FREE